In the current research, we sought to identify new compounds targeting both HCC (AFP+/CD133−) and LCSC (AFP+/CD133+) versus normal hepatocytes (AFP−/CD133−) in mixed HCC cell populations. The gene discussed is AFP; the disease is hepatocellular carcinoma.